- Abbott, Reata form $400M deal for second-generation AIMs
Reata Pharmaceuticals stands to receive $400 million from Abbott Laboratories as part of a research and development agreement centered on Reata's second-generation oral antioxidant inflammation modulators. The firms will co-develop the compounds and evenly split costs and profit for all compounds in all indications, excluding rheumatoid arthritis and certain autoimmune disorders. The agreement also calls for joint discovery of molecules with pharmacology similar to Reata's AIMs. PharmaTimes (U.K.) (12/12)        | Only in North Carolina can you find so many unique innovations to help heal, fuel AND feed the world. Discover NC’s complete package and why 538 companies call NC home. | | Health Care & Policy |  |  | | - Scientists find marker for precursors of blood stem cells
Researchers have found a molecular marker for blood stem cell precursors, according to a study published in Cell Stem Cell. "Understanding the developmental origins of hematopoietic stem cells is important for learning how to produce them in the lab from embryonic or induced pluripotent stem cells," said lead researcher Nancy Speck from the University of Pennsylvania. Yahoo!/Asian News International (12/10) - Peripheral blood stem cells from unrelated donors tied to greater risk
Patients with various types of high-risk leukemia who received peripheral blood stem cells, or PBSCs, from unrelated donors did not show greater survival rates and had a higher chance of developing chronic graft-versus-host disease, or GVHD, compared with patients who received bone marrow transplants from unrelated donors, according to a recent study. While previous studies have shown PBSCs from related donors to have clinical advantages, the current findings indicate that PSBCs from unrelated donors can lead to a higher risk of contracting chronic GVHD without similar benefits, the researchers said. HemOnc Today (12/11)  | Maximize Your Business's Potential.
Choose the American Express OPEN® Charge Card that's right for your established business.
• Purchasing Power
• Savings on business expenses
• Cash flow flexibility
• More rewards
American Express OPEN®. Apply Now. |
  - Onyx shares decline after accelerated review decision
Onyx Pharmaceuticals said the FDA set a July 27 target date for approval of multiple myeloma drug carfilzomib, denying an accelerated review. According to Onyx, the agency said the company hadn't undertaken clinical trials required for the quicker review. "We feel comfortable that we have addressed the key risks and that this is a compound that deserves to be approved either on an accelerated basis or a full basis," CEO Tony Coles said. Bloomberg Businessweek (12/13) - Expansion planned at Fitzsimons biotech park in Colorado
The Fitzsimons Redevelopment Authority in Colorado plans to spend $8 million to build a 37,000-square-foot "accelerator" facility at its Bioscience Park Center in Aurora. Authority official Denise Brown said the new facility will be rented to companies "in the modest growth stage." Five companies involved in the development of various therapeutic, diagnostic and medical device products have shown interest in renting space in the accelerator facility, said authority spokeswoman Vicki Jenings. The Denver Post (12/12)  | The Cutting Edge of Chemistry is a free report from Thomson Reuters, delivering an action-packed review of the latest synthesis schemes, scaffolds, mechanisms of action, and new structures shaping today's drug discovery and development pipeline. Extensively researched, this report gives you a deeper insight into the latest chemistry news that matters to you. Access the report here! |
 | Global Developments | | | | - Elan, Dublin university seal biotech partnership
Elan has forged a pact with the University College Dublin in Ireland as part of efforts to establish "a leadership position in the global biotechnology industry," beginning with the creation of the first biotech interdisciplinary chair in Europe. As part of the alliance, the university will receive more than $3.9 million from Elan for a new science facility. "The biotechnology industry require future business leaders ... to manage a portfolio of assets within the environment of a dynamic and ever-changing risks/reward equation," Elan chief executive Kelly Martin said. PharmaTimes (U.K.) (12/12) - India plans to map genome of coconut
India's Coconut Development Board is planning to partner with a genetic engineering company to map the genome of the coconut. "Once the genome is identified, it will help us cultivate various breeds of coconut according to our needs. We can produce short varieties of coconut trees or increase quality and yield," said board Chairman T K Jose. The Times of India (12/13)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| Food & Agriculture | | | | - Opinion: Africa needs biotechnology to solve food problems
African governments must adopt biotech crops to boost food production and alleviate hunger in the region, Matt Ridley writes in this Wall Street Journal opinion piece. The article builds on a Science magazine editorial by Calestous Juma, director of Harvard Kennedy School's Agricultural Innovation in Africa program, who argues that Africa badly needs biotechnology since most farmers in the region lack access to pesticides. The Wall Street Journal (12/10) | Industrial & Environmental | | | | | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | One is hardly sensible of fatigue while he marches to music."
--Thomas Carlyle,
Scottish writer and historian  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Monday, December 12, 2011
- Friday, December 09, 2011
- Thursday, December 08, 2011
- Wednesday, December 07, 2011
- Tuesday, December 06, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
1 comment:
Why Only in North Carolina?
License forms
sd
Post a Comment